Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer

نویسندگان

  • John Nemunaitis
  • Cynthia Bedell
  • Kevin Klucher
  • Alex Vo
  • Sam Whiting
چکیده

Background Mucin 1 (MUC1), a glycoprotein normally expressed at low levels on the apical borders of secretory epithelial cells, is overexpressed and aberrantly glycosylated in many cancers. ONT 10 is a therapeutic peptide vaccine incorporating a synthetic glycolipopeptide MUC1 antigen, M40Tn6, and novel synthetic TLR-4 agonist, PET Lipid A, in a liposomal formulation designed to elicit antibody and cellular immune responses.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.

BACKGROUND A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity. PATIENTS AND METHODS Seventy-four patients with advanced TA-MUC1-positive carcin...

متن کامل

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

PURPOSE Phase I clinical trials are generally conducted to identify the maximum tolerated dose (MTD) or the biologically active dose (BAD) using a traditional dose-escalation design. This design may not be applied to cancer vaccines, given their unique mechanism of action. The FDA recently published "Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines." However, many ...

متن کامل

Cancer Therapy: Clinical Is the "3þ3" Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design

Purpose: Phase I clinical trials are generally conducted to identify themaximum tolerated dose (MTD) or the biologically active dose (BAD) using a traditional dose-escalation design. This designmaynot be applied to cancer vaccines, given their unique mechanism of action. The FDA recently published "Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines." However, many qu...

متن کامل

نقش تکنولوژی در بهبود درمان سرطان

One major strategy, technology-driven improvement of treatment conformity in cancer treatment, including advanced image guidance, advanced charged particle therapy (CPT), and application of nanoparticles in hyperthermia, will enable further widening of the therapeutic window of cancer treatment in the era of precision medicine. The state­ of ­the ­art treatment in photon-therapy is advanced 3D...

متن کامل

Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice

Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80% of breast cancers.  In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 1  شماره 

صفحات  -

تاریخ انتشار 2013